|
|
|
News Releases |
 |
All Releases
 |
OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010
Jul 29, 2010
|
12.3 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jul 29, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter financial results will be released on Thursday, August 5, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon.
T...
|
|
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Jun 21, 2010
|
17.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Jun 21, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This tri...
|
|
OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors
Jun 7, 2010
|
18.5 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Jun 7, 2010 (Canada NewsWire via COMTEX News Network) -- Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced fina...
|
|
OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Jun 3, 2010
|
12.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jun 3, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m. ET at the New York Palace Hotel in New York Ci...
|
|
OncoGenex Pharmaceuticals to Present at the 6th Annual Rodman and Renshaw Global Healthcare Conference
May 13, 2010
|
12.7 KB |
|
| |
BOTHELL, WA,and VANCOUVER, May 13, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 6th Annual Rodman and Renshaw Global Healthcare Conference on May 17 at 4:30 p.m. BST (11:30 a.m. EDT) at the G...
|
|
OncoGenex Reports First Quarter Financial Results
May 6, 2010
|
20.6 KB |
|
| |
BOTHELL, WA, and VANCOUVER, May 6, 2010 (Canada NewsWire via COMTEX News Network) -- Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three months ended March 31, 2010 and reviewed the Company's high...
|
|
OncoGenex to Webcast First Quarter Financial Results on May 6, 2010
Apr 29, 2010
|
12.3 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Apr 29, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter financial results will be released on Thursday May 6, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Managemen...
|
|
OncoGenex Pharmaceuticals Awarded BIOTECanada's Biotech Company of the Year Award
Apr 8, 2010
|
14.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Apr 8, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will be presented with BIOTECanada's Gold Leaf Award as biotech company of the year. The award recognizes a biotech company that has distinguished itself from its peers with strong over...
|
|
Data from OncoGenex Pharmaceuticals' Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting
Mar 25, 2010
|
15.5 KB |
|
| |
BOTHELL, WA and VANCOUVER, Mar 25, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final results from a Phase 1 study evaluating OncoGenex' product candidate, OGX-427, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clini...
|
|
OncoGenex Adds Biopharmaceutical Industry Veterans to the Board of Directors
Mar 24, 2010
|
15.3 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Mar 24, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Dr. Jack Goldstein and Ms. H. Stewart Parker to its board of directors. In addition, Dr. Martin Mattingly has agreed to stand for election at the Company's upcoming A...
|
|
Peer-reviewed Research Elucidates Function of Hsp27; Supports OGX-427 Approach Targeting Cancer Treatment Resistance
Mar 15, 2010
|
17.8 KB |
|
| |
BOTHELL, WA and VANCOUVER, Mar 15, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed manuscripts have been published that provide additional insight into the function of Heat Shock Protein 27 (Hsp27) and its role in promoting tumor resistance to cancer treatment....
|
|
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010
Mar 8, 2010
|
22.6 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Mar 8, 2010 (Canada NewsWire via COMTEX News Network) -- Conference Call on Monday, March 8, 2010 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), today announced its fourth quarter and fiscal year 2009 financial results, reviewed the Company's highlights and pr...
|
|
OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Mar 4, 2010
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, WA, Mar 4, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2009 financial results will be released at the market close on Monday, March 8, 2010, and that the Company will host a conference call and live webca...
|
|
Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer
Mar 1, 2010
|
16.5 KB |
|
| |
BOTHELL, WA and VANCOUVER, Mar 1, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor ...
|
|
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Mar 1, 2010
|
11.9 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Mar 1, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the RBC Capital Markets' Healthcare Conference on a panel titled "Cancer: Improving Treatment Through Combination T...
|
|
The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer
Feb 25, 2010
|
15.9 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Feb. 25, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic c...
|
|
OncoGenex Announces Departure of Chief Financial Officer
Feb 25, 2010
|
13.6 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Feb. 25, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company and Steve Anderson, its chief financial officer, have agreed that he will leave the Company effective yesterday.
OncoGenex has initiated an executive search to identify a CFO c...
|
|
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding
Jan 6, 2010
|
16.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Jan. 6, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has rec...
|
|
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Dec 21, 2009
|
20.2 KB |
|
| |
JERUSALEM, Israel, BOTHELL, WA and VANCOUVER, Canada, Dec. 21, 2009 (Canada NewsWire via COMTEX News Network) -- -- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 --
-- Significantly strengthens Teva's oncology offerings with novel therapeut...
|
|
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
Dec 20, 2009
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Dec. 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.
A live webcast will be available through the Investor Relations page of the OncoGenex Web si...
|
|
|
= add release to Briefcase
|
|
|
|
0.01
